SNRI
An SNRI, or serotonin and norepinephrine reuptake inhibitor, is a type of antidepressant that slows the return of two chemical messengers, serotonin and norepinephrine, into nerve cells. The class prescribed in the US is venlafaxine (Effexor XR), duloxetine (Cymbalta), desvenlafaxine (Pristiq) and levomilnacipran (Fetzima), and the first two are the ones most people meet.
Also called: Serotonin and norepinephrine reuptake inhibitor, SNRIs.
Written by Alena Kozlova, PhD, from published studies and prescribing information.
Definition medically reviewed by Dr. Jason Tan, Consultant Psychiatrist, on November 11, 2026, this definition only. Next review: November 11, 2027.
What is the difference between an SSRI and an SNRI?
An SSRI acts on serotonin alone. An SNRI acts on serotonin and on norepinephrine, which the Effexor XR (venlafaxine) label describes as potentiation of both in the central nervous system through inhibition of their reuptake. The approved uses overlap a lot. Effexor XR covers major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder, and much of the SSRI list covers the same ground.
The norepinephrine side shows up in what gets monitored. The Effexor XR label reports dose-related rises in blood pressure, and the US duloxetine label asks for blood pressure to be measured before treatment starts and from time to time during it.
Is SNRI a stimulant?
No. Stimulants are a separate class. MedlinePlus puts Adderall, which is dextroamphetamine and amphetamine, in a class called central nervous system stimulants, used for ADHD and narcolepsy. An SNRI works by slowing the reuptake of serotonin and norepinephrine, and it is prescribed for depression and anxiety.
The mix-up makes sense, because starting an antidepressant can feel activating: restless, wired, hard to sit still or hard to sleep. In a 2017 study of 209 people starting one of five antidepressants, one of them the SNRI desvenlafaxine, jitteriness turned up in 27.7% over six weeks but in only 6.7% during the first two weeks, so it tends to arrive after the first fortnight rather than on day one. A higher dose raised the odds. That study gives no separate figure for desvenlafaxine, and its five drugs ranged from 14.3% on mirtazapine to 23% and 34% for the rest, so the number describes starting an antidepressant in general. Tell your prescriber if it does not settle.
Who should avoid SNRI?
Four groups, by the US labels. Anyone taking a monoamine oxidase inhibitor, or less than 14 days off one. Anyone whose blood pressure is not under control, since the Effexor XR label asks prescribers to control pre-existing hypertension before treatment with Effexor XR starts. Anyone with substantial alcohol use or evidence of chronic liver disease, who should not be prescribed duloxetine at all. And anyone who has reacted badly to the drug itself before.
The alcohol rule sits in the duloxetine label under its hepatotoxicity warning, so what it is guarding against is liver injury.
Blood pressure is the check that follows the rest of you onto the prescription. In the Effexor XR trials, 1.4% of people had a supine diastolic rise of at least 15 mm Hg to 105 mm Hg or more, against 0.9% on placebo. The duloxetine label puts the mean rise at 0.5 mm Hg systolic and 0.8 mm Hg diastolic against placebo, which is small on average and still worth measuring, because the average hides the people at the far end.
The gap around an MAOI runs both ways: 14 days after an MAOI before an SNRI starts, and 5 to 7 days after an SNRI before an MAOI, depending on which one you are on. Your prescriber names the date. Antidepressants also carry a boxed warning about suicidal thoughts and behaviors in children, teenagers and young adults, so the first weeks and any dose change need watching.
Is an SNRI better for anxiety?
Neither class wins. In a network meta-analysis of 89 trials and 25,441 people with generalized anxiety disorder, duloxetine, venlafaxine and escitalopram were all more effective than placebo with relatively good acceptability, an SNRI and an SSRI side by side. Paroxetine and benzodiazepines worked too but were tolerated less well.
The labels line up the same way. Effexor XR is approved for generalized anxiety disorder, social anxiety disorder and panic disorder. Duloxetine is approved for generalized anxiety disorder in adults and in children from age 7. Lexapro, an SSRI, is approved for generalized anxiety disorder down to age 7, and Zoloft, an SSRI, for panic disorder, social anxiety disorder and post-traumatic stress disorder.
Which one fits you depends on what you have already tried, your blood pressure, your other conditions and the side effects you can live with. Ask your prescriber what they are weighing, and say which side effects would be hardest for you.
Why would doctors prescribe SNRI instead of SSRI?
Often because an SSRI did not do enough, or because something else needs covering at the same time. Duloxetine is approved for five conditions: major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain, which covers chronic low back pain and osteoarthritis pain. So one medicine can sit across pain and mood, and that is the commonest reason an SNRI comes up instead of an SSRI.
The class has grown. In a US survey of adults with major depression between 1996 and 2015, SNRIs went from 3.3% of antidepressant prescriptions to 16.4%, while the SSRI share stayed near 70%.
People also ask whether an SNRI is harder to come off than an SSRI. The labels ask for the same thing, a gradual reduction in the dose rather than abrupt cessation. The reports differ, though. In an analysis of 31,688 withdrawal reports in the WHO safety database, the strongest signals were for paroxetine, duloxetine, venlafaxine and desvenlafaxine, and the Effexor XR label itself says that for some people coming off needs to happen over several months. So with venlafaxine or duloxetine the taper is worth planning early and slowly with your prescriber, rather than at the last appointment.
What to do
Ask your prescriber why an SNRI rather than an SSRI, what your blood pressure was before you started, and when it gets checked again. Write down the start date, the dose, and anything new in sleep, restlessness or headaches, with the day it began. Do not stop an SNRI on your own: the US labels ask for a gradual reduction rather than an abrupt stop. If you’re having thoughts of harming yourself, contact emergency services or a crisis line straight away. In the US, call or text 988. In the UK, call Samaritans on 116 123. Elsewhere, find a crisis line near you.
See the venlafaxine page
How withClaro helps
- A daily log of how you feel, next to the dose you took
- A PDF report for your prescriber before the appointment
Get the withClaro app on the App Store
Related terms
Sources
- U.S. Food and Drug Administration. Effexor XR (venlafaxine extended-release capsules): prescribing information. FDA / DailyMed, 2025.
- Eli Lilly and Company. Cymbalta (duloxetine delayed-release capsules): prescribing information. Eli Lilly, 2023.
- U.S. Food and Drug Administration. Lexapro (escitalopram) tablets and oral solution: prescribing information. FDA / DailyMed, 2026.
- U.S. Food and Drug Administration. Zoloft (sertraline) tablets and oral solution: prescribing information. FDA / DailyMed, 2025.
- Sinha P, Shetty DJ, Bairy LK, Andrade C. Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors. Asian Journal of Psychiatry, 2017.
- Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet, 2019.
- Gastaldon C, Schoretsanitis G, Arzenton E, Raschi E, Papola D, Ostuzzi G, Moretti U, Seifritz E, Kane JM, Trifiro G, Barbui C. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database. Drug Safety, 2022.
- Luo Y, Kataoka Y, Ostinelli EG, Cipriani A, Furukawa TA. National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis. Frontiers in Psychiatry, 2020.
All glossary terms